Improvement of nonsuicidal self-injury following treatment with antipsychotics possessing strong D1 antagonistic activity: evidence from a report of three cases

Abstract

Introduction: There is no drug treatment for nonsuicidal self-injury (NSSI), a highly prevalent and burdensome symptom of several psychiatric diseases like posttraumatic stress disorder (PTSD), personality disorders, and major depression (MD). Methods:Here, we present a retrospective series of three patients demonstrating a persistent remission in MD-associated NSSI in response to treatment with antipsychotics possessing marked D1 receptor antagonistic activity. Results: To the best of the authors' knowledge, the case series presented is only the second clinical paper suggesting a role for D1 antagonists in NSSI drug therapy. Conclusions: Together with previously published data from rodent models, the findings suggest a role for D1 antagonists in NSSI drug therapy and hence for the D1 receptor in NSSI pathogenesis. This conclusion is limited by the facts that the patients presented here received polypharmacy and that the D1 receptor antagonistic antipsychotics suggested here as effective 'anti-auto-aggressants' do not address D1 receptors only but multiple neurotransmitter receptors/systems.

Pharmacological Support Treatment of Non-Suicidal Self-Injuries Among Children and Adolescents: A Narrative Review

“…A series of case reports suggests that impaired dopaminergic transmission, associated with dopamine 1 (D1) receptors, may partially contribute to the occurrence of NSSI -the use of such neuroleptics like zuclopenthixol or flupentixol, and their antagonism towards the mentioned D1 receptors, may be effective in reducing the incidence of self-harm [33].…”